Suffice it to say, it has been a banner week in the world of stem cells. In this rapidly-changing market environment, it can be difficult to keep up with current events. To help you out, we’ve released new content on stem cell markets that we are excited to share with you. Let me know what you think! [Read more…]
Breaking: Cynata Reports Extremely Positive Interim Data for MSC Product, CYP-001, in Model of GvHD
Australian stem cell company Cynata Therapeutics released news today than interim analysis clearly demonstrates efficacy of Cynata’s unique Cymerus™ mesenchymal stem cell (MSC) product, CYP-001, in a preclinical model of Graft-versus-Host disease (GvHD). This disease often follows a bone marrow transplant procedure and occurs when the immune cells in the donor material (the graft) attack the recipient’s tissues (the host) as “foreign”. Bone marrow transplants are used in the treatment of certain cancers, including leukaemia. [Read more…]
Did You Hear About These Stem Cell Events?
The stem cell sector is fueled by innovation and rapid change. To keep you up-to-date, we recently released new coverage of the industry. Check it out and let us know what you think! [Read more…]
Cynata Therapeutics Enters Agreement for Strategic Alliance with Regience K.K. in Japan
In recently released news, Cynata Therapeutics announced that it has entered into a strategic alliance with Regience K.K., who will have an exclusive 2-year option to license Cynata’s unique Cymerus™ technology in Japan and certain other Asian countries.
Cynata’s Cymerus™ technology produces clinical-grade mesenchymal stem cells (MSCs) derived from a one-time donation from a single donor, using induced pluripotent stem cells (iPSCs) as the source tissue. This approach allows MSCs to be produced in nearly limitless quantities, eliminates product variability, and allows for lower manufacturing costs.
Cynata is an exciting company to watch, as highlighted by Rodman and Renshaw. To learn more, read the full press release from Cynata Therapeutics, included below. [Read more…]
Why Perinatal Stem Cells Are Gaining Momentum
Recently back from the Perinatal Stem Cell Society Conference in Aspen, CO, I am excited to share new coverage of the stem cell market with you. At this event, experts from around the world shared cutting-edge research about perinatal tissues over the course of three days (March 2-4, 2016).
We also have interviews with stem cell executives released below, including an interview with Dr. Jon Rowley, Founder and CEO of RoosterBio, and Dr. Racheli Ofir, VP of Research & Intellectual Property at Pluristem Therapeutics. Enjoy this exclusive new content!
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- 9
- Next Page »